patent

Compositions and methods for protecting neural tissue (e.g.,
neurons) from anoxia and spreading depression (SD) involve
inhibiting the cGMP-dependent protein kinase (PKG) pathway.
It was discovered that the PKG pathway plays a crucial
role in regulating SD and tolerance to anoxia in the central
nervous system (CNS). Inhibition of the PKG pathway
greatly reduces SD and increases tolerance to anoxia (i.e.,
hypoxia), while activation of the pathway exacerbates SD
pathology. The compositions and methods can be used to treat
any condition associated with SD or anoxia, including stroke,
spinal cord injury, neurogenerative disease, dizziness, headaches,
and migraines.

Compositions and methods for protecting neural tissue (e.g.,
neurons) from anoxia and spreading depression (SD) involve
inhibiting the cGMP-dependent protein kinase (PKG) pathway.
It was discovered that the PKG pathway plays a crucial
role in regulating SD and tolerance to anoxia in the central
nervous system (CNS). Inhibition of the PKG pathway
greatly reduces SD and increases tolerance to anoxia (i.e.,
hypoxia), while activation of the pathway exacerbates SD
pathology. The compositions and methods can be used to treat
any condition associated with SD or anoxia, including stroke,
spinal cord injury, neurogenerative disease, dizziness, headaches,
and migraines.

A pharmaceutical composition for treating or preventing one
or both of neural anoxia and reperfusion injury, which
includes a pharmacological activator of the PKG pathway,
and methods of treating or preventing medical conditions
using a pharmacological activator of the PKG pathway.

A pharmaceutical composition for treating or preventing one
or both of neural anoxia and reperfusion injury, which
includes a pharmacological activator of the PKG pathway,
and methods of treating or preventing medical conditions
using a pharmacological activator of the PKG pathway.

Compositions and methods for reducing neovascularization.
Purified nucleic acid constructs and vectors encoding an antiangiogenic
protein operably linked to a GFAP promoter. Vectors
can include at least one hypoxia regulated element,
enhancer element and silencer element. Gene therapy methods
for reducing, delaying or preventing neovascularization
based on the nucleic acid constructs and vectors.

Clonal strains of bacteria derived from Pseudopterogorgia
elisabethae are capable of making pseudopterosins in in vitro
cultures without requiring the presence of other bacteria,
algae, or animal cells that are normally present in P. elisabethae.

Clonal strains of bacteria derived from Pseudopterogorgia
elisabethae are capable of making pseudopterosins in in vitro
cultures without requiring the presence of other bacteria,
algae, or animal cells that are normally present in P. elisabethae.